Catalent has launched Qai, its first enterprise AI solution, as part of the company's broader digital transformation strategy aimed at enhancing quality management processes across its global network. Designed to strengthen operational consistency and improve decision-making, Qai leverages enterprise data and AI-driven insights to support critical quality management workflows within pharmaceutical and biotechnology manufacturing environments.
The new platform reflects Catalent's ongoing investment in advanced technologies that help improve operational efficiency, regulatory compliance, and patient outcomes while supporting the growing needs of life sciences organizations worldwide.
As pharmaceutical and biotechnology organizations face increasing operational complexity and regulatory requirements, AI is becoming an important tool for improving quality management and manufacturing efficiency. Catalent's Qai platform is designed to address these challenges by embedding AI capabilities directly into existing quality management systems.
The platform strengthens key processes such as deviations, complaints, root cause analysis, and corrective and preventive action (CAPA) development. By leveraging enterprise-wide data, Qai helps teams identify issues faster, improve reporting accuracy, and streamline quality-related workflows.
“The launch of Qai represents an important milestone in how Catalent is applying advanced technologies, including AI, across our operations to improve consistency, accelerate insight and enable better decision-making,” said Charlie Lickfold, Chief Technology Officer, Catalent.
“Innovative AI solutions like Qai strengthen the quality of our operations and better support the teams delivering critical therapies to patients around the world.”
Qai was developed with support from Microsoft and is powered by Microsoft Azure AI technologies. The platform utilizes Microsoft Foundry alongside data and analytics capabilities from Microsoft Fabric to deliver intelligent insights within Catalent's operational environment.
By integrating AI directly into quality workflows, the platform enables faster analysis, more consistent decision-making, and improved operational visibility. According to Catalent, Qai also helps reduce repeat deviations, accelerate reporting processes, and minimize documentation bottlenecks that can impact productivity and compliance efforts.
The solution is designed to support quality teams by reducing administrative burdens and enabling greater focus on customer and patient outcomes.
Qai incorporates intelligent recommendations and data-driven analysis to strengthen oversight across manufacturing and quality operations. The platform's ability to improve root cause identification and corrective action planning is expected to help organizations enhance compliance while driving operational improvements across the product lifecycle.
Catalent views AI as a strategic enabler for delivering measurable business value while supporting its Patient First operating philosophy. The company believes technologies such as Qai can help simplify complex processes and improve consistency across its global manufacturing network.
“Qai reflects what we see as an important application of AI in life sciences: enhancing already robust data analytics and governance to deliver meaningful patient impact,” said Todd Mersch, General Manager, U.S. Life Sciences and MedTech, Microsoft.
“By strengthening oversight and consistency across manufacturing processes, Qai supports Catalent’s commitment to delivering for customers and the patients they serve, helping to transform lives.”
As part of its AI initiatives, Catalent emphasizes the ethical and responsible deployment of artificial intelligence technologies. The company has established governance frameworks focused on transparency, accountability, fairness, and human oversight to guide the development and implementation of AI solutions.
Catalent stated that its approach seeks to mitigate risks, address ethical considerations, and ensure AI technologies deliver positive outcomes for customers, employees, patients, and broader stakeholders.
The launch of Qai represents another step in Catalent's effort to modernize operations through digital innovation while supporting the evolving requirements of pharmaceutical and biotech manufacturers. As AI adoption continues to expand across life sciences, the company aims to leverage intelligent technologies to improve operational performance, strengthen quality management, and enhance patient outcomes worldwide.
About AI at Catalent
As part of its AI journey, Catalent continuously seeks to promote the ethical and responsible use of AI. Catalent prioritizes transparency, accountability and fairness in all AI initiatives. Catalent’s governance framework supports the development and deployment of AI technologies with human oversight and judgment, aligning with company core values and ethical standards. The company continuously strives to mitigate risks and address ethical considerations, in line with its ambition to ensure AI solutions benefit all stakeholders, contribute positively to society and amplify Catalent’s mission and Patient First culture.
The launch of Qai underscores Catalent’s continued investment in digital transformation and innovation, advancing the capabilities needed to support the evolving demands of pharmaceutical and biotech customers and improve patient outcomes worldwide.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
